Cardax (CDXI) Price & Analysis

2 Followers

CDXI Stock Chart & Stats

$0.43

$0.00(0.00%)

At close: Mar 12 4:00 PM EDT

$0.43

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.43 - $0.45

Previous CloseN/A

Volume20.00

Average Volume (3M)0.00

Market Cap

$80.00

Enterprise Value$4.76M

Total Cash (Recent Filing)$58.65K

Total Debt (Recent Filing)$5.40M

Price to Earnings (P/E)―

Beta125.33

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.03

Shares Outstanding802,516

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-0.12

Price to Sales (P/S)2.35

P/FCF Ratio-0.70

Enterprise Value/Market Cap59.56K

Enterprise Value/Revenue9.52

Enterprise Value/Gross Profit14.47

Enterprise Value/Ebitda-1.57

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

CDXI FAQ

What was Cardax’s price range in the past 12 months?

Cardax lowest stock price was $0.43 and its highest was $0.45 in the past 12 months.

What is Cardax’s market cap?

Cardax’s market cap is $80.00.

When is Cardax’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Cardax’s earnings last quarter?

Cardax released its earnings results on May 14, 2021. The company reported -$1.74 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.74.

Is Cardax overvalued?

According to Wall Street analysts Cardax’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cardax pay dividends?

Cardax does not currently pay dividends.

What is Cardax’s EPS estimate?

Cardax’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cardax have?

Cardax has 802,516 shares outstanding.

What happened to Cardax’s price movement after its last earnings report?

Cardax reported an EPS of -$1.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Cardax?

Currently, no hedge funds are holding shares in CDXI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cardax

Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.